Ori Biotech Nabs $120 Million Contract to Integrate Its Automated Cell Therapy Manufacturing Platform

The deal includes up to $120 million in services, milestones, equipment, and consumable purchases over a 10-year term with an undisclosed biopharmaceutical partner.

Key Points

  • Ori Biotech has announced a 10-year collaboration valued at up to $120 million to integrate its IRO platform into an undisclosed partner’s commercial autologous cell therapy manufacturing process.
  • The IRO platform is a GMP-ready automated system combining hardware, consumables, software, and data analytics, and received FDA Advanced Manufacturing Technology designation in June 2025.
  • The partners plan to demonstrate comparability of the IRO process with the existing commercial manufacturing process, with the first patient dosed with an IRO-manufactured therapy in May 2026.

Ori Biotech, a cell and gene therapy manufacturing technology company, has announced a strategic collaboration with an undisclosed biopharmaceutical company to integrate the IRO platform into a commercial autologous cell therapy manufacturing process. The deal is valued at up to $120 million in services, milestones, equipment, and consumable purchases over the next 10 years. The collaboration is designed to modernize the partner’s autologous cell therapy manufacturing infrastructure with the aim of expanding patient access to current and future cell therapies.

The IRO platform combines proprietary hardware, consumables, software, and data analytics in a closed, GMP-ready system. Designed to support the full journey from R&D through commercial manufacturing on a single platform, IRO is intended to address core challenges of autologous cell therapy production: reducing batch-to-batch variability, minimizing operator touch time, increasing throughput, and lowering cost of goods sold. The platform received Advanced Manufacturing Technology designation from the FDA in June 2025.

Through the collaboration, the parties will work together to demonstrate comparability of the IRO process to the existing commercial manufacturing process, with the aim of building a flexible and scalable manufacturing infrastructure that can support ongoing commercial supply as well as future development and commercialization needs. Since its launch in 2024, IRO has gained 23 partners. In May 2026, the first patient was dosed with a therapy manufactured on the IRO platform and released under GMP.

Leadership Comments

“Our newest partner has made an important commitment to further advancing its cell therapy capabilities at a time when the field needs dedicated, patient-focused organizations to help bring these therapies to patients,” said Jason C. Foster, CEO of Ori Biotech. “We are proud to be their chosen manufacturing technology partner. The IRO platform was built precisely for this challenge: to give therapy developers the scalability, reproducibility and cost efficiency they need to realize both the clinical and commercial benefits of these groundbreaking therapies. Together, we are committed to ensuring that the appropriate patients have access to these potentially transformative therapies.”

“The IRO technology continues to fulfill the promise of Ori’s mission to enable widespread patient access to potentially life-saving cell and gene therapies. Ori’s rapidly growing list of partnerships across leading therapy developers, academic institutions and CDMOs puts the company at the forefront of supporting the indications within oncology and immunology in which these therapies are transforming the lives of patients globally,” said Dr. Annalisa Jenkins, Board Chair of Ori Biotech. “This collaboration will allow our partner to unlock true automation and open up access for more patients without having to sacrifice the biological performance of their pioneering therapy.”

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.

Similar stories